Evidence map›Paper›PMID 22693634›Full record

ArticlePloS one2012

SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responses.

Cortez McBerry, Rosa Maria Salazar Gonzalez, Nathaniel Shryock, Alexandra Dias, Julio Aliberti

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. SOCS2 regulates alveolar bone loss in Aggregatibacter actinomycetemcomitans-induced periodontal disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Frontiers in immunology · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cortez McBerryDivisions of Molecular Immunology and Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Rosa Maria Salazar Gonzalez
Nathaniel Shryock
Alexandra Dias
Julio Aliberti
Cincinnati Children's Hospital Medical Center · US

Funding

Control of Immune responses by lipoxins during tuberculosisR01AI075038 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI ALIBERTI, JULIO · 2008 to 2012
$1.7M
Innate Immune Responses during ToxoplasmosisR01AI078969 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI ALIBERTI, JULIO · 2009 to 2010
$761k
NIAID NIH HHS AI075038NIAID NIH HHS AI078969NIAID NIH HHS R01 AI075038NIAID NIH HHS R01 AI078969
6 · The paper itself

Abstract

Pattern recognition receptors and receptors for pro-inflammatory cytokines provide critical signals to drive the development of protective immunity to infection. Therefore, counter-regulatory pathways are required to ensure that overwhelming inflammation harm host tissues. Previously, we showed that lipoxins modulate immune response during infection, restraining inflammation during infectious diseases in an Aryl hydrocarbon receptor (AhR)/suppressors of cytokine signaling (SOCS)2-dependent-manner. Recently, Indoleamine-pyrrole 2,3- dioxygenase (IDO)-derived tryptophan metabolites, including L-kynurenine, were also shown to be involved in several counter-regulatory mechanisms. Herein, we addressed whether the intracellular molecular events induced by lipoxins mediating control of innate immune signaling are part of a common regulatory pathway also shared by L-kynurenine exposure. We demonstrate that Tumor necrosis factor receptor-associated factor (TRAF)6--member of a family of adapter molecules that couple the TNF receptor and interleukin-1 receptor/Toll-like receptor families to intracellular signaling events essential for the development of immune responses--is targeted by both lipoxins and L-kynurenine via an AhR/SOCS2-dependent pathway. Furthermore, we show that LXA₄- and L-kynurenine-induced AhR activation, its subsequent nuclear translocation, leading SOCS2 expression and TRAF6 Lys47-linked poly-ubiquitination and proteosome-mediated degradation of the adapter proteins. The in vitro consequences of such molecular interactions included inhibition of TLR- and cytokine receptor-driven signal transduction and cytokine production. Subsequently, in vivo proteosome inhibition led to unresponsiveness to lipoxins, as well as to uncontrolled pro-inflammatory reactions and elevated mortality during toxoplasmosis. In summary, our results establish proteasome degradation of TRAF6 as a key molecular target for the anti-inflammatory pathway triggered by lipoxins and L-kynurenine, critical counter-regulatory mediators in the innate and adaptive immune systems.

Indexed as

AnimalsFlow CytometryImmunity, InnateInterferon-gammaMiceMice, Inbred C57BLProteasome Endopeptidase ComplexReal-Time Polymerase Chain ReactionSuppressor of Cytokine Signaling ProteinsTNF Receptor-Associated Factor 6Tumor Necrosis Factor Receptor-Associated Peptides and ProteinsUbiquitinationInterferon-gammaProteasome Endopeptidase ComplexSocs2 protein, mouseSuppressor of Cytokine Signaling ProteinsTNF Receptor-Associated Factor 6Tumor Necrosis Factor Receptor-Associated Peptides and Proteins

Identifiers

PMID22693634
PMCPMC3367914
OpenAlexW2063863569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.